| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BREAST.2005.08.026 |
| P698 | PubMed publication ID | 16199161 |
| P50 | author | Raquel Muñoz | Q56550045 |
| Francesco Bertolini | Q56850281 | ||
| P2093 | author name string | Robert S Kerbel | |
| Yuval Shaked | |||
| Shan Man | |||
| Urban Emmenegger | |||
| P433 | issue | 6 | |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 466-479 | |
| P577 | publication date | 2005-09-30 | |
| P1433 | published in | The Breast | Q7719928 |
| P1476 | title | Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy | |
| P478 | volume | 14 |
| Q37310699 | Acrolein: unwanted side product or contribution to antiangiogenic properties of metronomic cyclophosphamide therapy? |
| Q42037461 | Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2 |
| Q26822432 | Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials |
| Q37528441 | Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
| Q37008618 | Antiangiogenic agents in breast cancer |
| Q37498953 | Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer |
| Q37086200 | Combination of metronomic cyclophosphamide and dietary intervention inhibits neuroblastoma growth in a CD1-nu mouse model |
| Q37259624 | Dendritic cell-based cancer vaccination: quo vadis? |
| Q49544357 | Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer |
| Q33485606 | Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice |
| Q41905174 | Integrin imaging to evaluate treatment response |
| Q36359098 | Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit. |
| Q39765023 | Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice |
| Q33794896 | Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care |
| Q27023579 | Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance |
| Q37942484 | Metronomic therapy concepts in the management of adrenocortical carcinoma |
| Q38218923 | Metronomics: towards personalized chemotherapy? |
| Q92062546 | Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options |
| Q38322346 | Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue? |
| Q90134757 | Oral medications for central serous chorioretinopathy: a literature review |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q55313600 | Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy. |
| Q57821563 | The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells |
| Q57578409 | The concept of mathematically optimised dose-scheduling as applied to the adjuvant chemotherapy of primary breast cancer: theory and recent results |
| Q42573450 | The emerging low-dose therapy for advanced cancers |
| Q33884698 | Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer |
| Q35309992 | Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin |
| Q39413633 | VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. |
| Q58251307 | Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients |
| Q53550522 | [Efficacy of continuous low-dose cyclophosphamide and prednisone regimen in refractory multiple myeloma patients with severe heart failure]. |
Search more.